Search PubMed⌕ Search

Biomedical subjects

V Boneschi

Publications and source records attributed to V Boneschi.

36 records · Page 2Linked to original sources
PubMed1990

Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon.

We investigated the peritumoral and intratumoral immune infiltrate in 6 basal cell carcinomas (BCCs) treated with recombinant alpha 2b-interferon. Each BCC was injected intralesionally three times a week for 3 weeks with 1.5 x 10(6) IU of interferon per injection (total dose 13.5 x 10(6) IU). The immunohistological study was done before the start of interferon therapy and 15 days afterwards, using a series of monoclonal antibodies and an immunocytochemical technique. Before therapy the infiltrate consisted mainly of CD3+ (T) cells, with prevalence of CD4+ (helper/inducer) T cells. The percentage of T cells expressing interleukin-2 receptor (CD25+ cells) was higher in the tumor nests than in the peritumoral infiltrate (20% and 11% respectively). CD1+ (Langerhans) cells and CD14b+ cells (monocytes/macrophages) were present in the peritumoral infiltrate in all cases (9% +/- 5% and 14% +/- 7% respectively). Very few CD56+ (natural killer), CD15+ (granulocytes) and CD20+ (B) cells were observed in the peritumoral infiltrate and none at all in tumor nests. After 15 days of interferon therapy, we observed an increase in peritumoral and intratumoral CD4+ cells. There was a decrease in the number of CD25+ cells and of CD1+ cells in the peritumoral infiltrate. The number of intratumoral CD25+ increased. No variations were seen in CD14b, CD15, CD20, and CD56 positive cells. Eight weeks after completion of therapy, two BCCs were cleared and the remaining four showed clinical and histological improvement. These results may indicate a direct effect of interferon against BCC; in addition the immunohistological findings suggest that intralesional interferon enhances T cell mediated immune response, especially in tumor nests.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed1990

[Structural and ultrastructural study of an isolated case of pili annulati].

A case of pili annulati in an eighteen year old woman is described. The hairs show bright spots along hair shafts when viewed in daylight. The transmission and scanning electron microscopy confirmed that the bright spots are due to small cavities into the cortex. The plasmatic measurement of copper, zinc and of the most important hormone, such as the dosage of plasmatic, urinary and hair aminoacids, allowed the Authors to exclude any influence of metabolic systemic alterations on the pathogenesis of pili annulati. Neither cutaneous nor internal anomalies were detected.

Adolescent↗
PubMed1989

[Late secondary syphilis].

A case of late secondary syphilis characterized by morphologically and topographically typical papulo-nodular and nodulo-ulcerative lesions is described. In the course of the late secondary stage nodular and ulcerous lesions arise as precursors of the tertiary stage. Therapy with penicillin caused the rapid regression of the disease with slight residual atrophy and dyschromia.

Humans↗
PubMed1988

Annular elastolytic giant cell granuloma.

We treated a 13-year-old girl who had annular erythematous lesions with central atrophic areas, which had been present on her trunk and limbs for 4 months. Histological examination revealed patchy dermal lymphohistocytic infiltration with multinucleated giant cells which were phagocytosing elastic fibers, causing them to disappear. The active border of the lesions regressed after intradermal injection of corticosteroids. The classification of the disease and its differential diagnosis from the usual granuloma annulare, inflammatory anetoderma, O'Brien's actinic granuloma, and Convit's disease are discussed.

Adolescent↗
PubMed1988

Oral etoposide for Kaposi's Mediterranean sarcoma.

22 patients affected by locally aggressive or generalized form of Kaposi's Mediterranean sarcoma were treated with oral etoposide (VP16) as single-drug therapeutic regimen. Of the 17 evaluable patients, 10 were pretreated with other chemotherapeutic regimens. VP16 was administered at the dose of 100 mg daily for 3-5 days every 3 weeks for 3 times during induction, then every 4 weeks for 10-12 times during maintenance. Hematological (35.2%) and gastrointestinal (64.7%) toxicities were always mild and swiftly reversible. Good percentages of objective responses were achieved in both nonpretreated (85.6%) and pretreated (70%) patients. The chemotherapeutic regimen employed, the way of drug administration, the results as well as the comparison to another study with vinblastine are discussed.

Administration, Oral↗
PubMed1987

Histological and immunological features of primary Kaposi's sarcoma: evaluation before and after chemotherapy.

Forty-one patients with primary Kaposi's sarcoma (KS) have been evaluated clinically, histologically and immunologically at the time of diagnosis. There was no correlation between histological and immunological features. Moreover, the disease did not appear to be related to particular HLA phenotypes. The T4/T8 ratio was augmented. Leu 7+ cells were also significantly increased. The last 15 patients who received chemotherapy were recently reevaluated after treatment and an increase in B lymphocytes was observed. We also observed that spindle-shaped cells (SSC), which appear later in the histopathological course of the disease, disappear first during chemotherapy, concomitantly with the increase in B cells. We conclude that the course of the disease appears to be controlled by the host's immune response, though there is no clear correlation between histological and immunological evolution. Several immunological features differentiating it from AIDS associated KS have been found.

Aged↗
PubMed1985

Immunologic and immunogenetic features of primary Kaposi's sarcoma.

In order to establish if immunologic alterations seen in acquired immunodeficiency syndrome (AIDS)-associated Kaposi's sarcoma are also present in the primary form of this malignancy, peripheral blood T-lymphocyte characterization and HLA A, B, C, and DR phenotyping have been carried out in 18 patients with the primary form of the disease. HLA antigen distribution was not significantly different from that of the normal population and, in particular, DR5 was only marginally increased. The T4/T8 ratio was significantly higher in the patients than in the control group, and this was due to a marked decrease in suppressor cells. The possible pathogenetic relevance of these findings is discussed.

Aged↗
PubMed1984

Intralesional chemotherapy for Kaposi's sarcoma.

Over a period of 36 months we treated 12 patients with skin localizations of Kaposi's sarcoma with intralesional chemotherapy. Local administration of vincristine (usual dose 0.1 mg per site) or bleomycin appeared to be very effective: in 93 injected nodules we obtained 74 complete and 19 partial regressions. No significant local or systemic toxicity has so far been observed.

Aged↗
PubMed1984

Unusual cases of Meleda keratoderma treated with aromatic retinoid etretinate.

We studied a brother and sister of South Italian origin with palmoplantar keratoderma which, because of the clinical aspects (transgrediens et progrediens), mode of inheritance (autosomal recessive) and evolution, we diagnosed as Meleda keratoderma with particular clinical features (presence of ainhum-like narrowings and concomitant lesions at other sites). Appropriate classical histologic and familial investigations, as well as HLA typing were done, and retinol-binding protein values were determined. The patients were treated with the aromatic retinoid etretinate, and the clinical and histological results after 9 months' treatment are reported.

Adult↗